Cholesteryl ester transfer protein: Gathering momentum as a genetic marker and as drug target

Current Opinion in Lipidology

Volumn 14, Issue 2, 2003, Pages 173-178

  Ritsch, Andreas ^a   Patsch, Josef R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Atherosclerosis; Cardiovascular disease; High density lipoprotein; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CASE REPORT; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DRUG TARGETING; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HYPERLIPOPROTEINEMIA; MEDICAL DECISION MAKING; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN VARIANT; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; GENETIC MARKERS; GLYCOPROTEINS; HUMANS; SUBSTRATE SPECIFICITY;

EID: 0037396823     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200304000-00009     Document Type: Review

References (56)

1. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323:1234-1238.
2. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97:2917-2923.
3. Moriyama Y, Okamura T, Inazu A, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998; 27:659-667.
4. Plump AS, Masucci-Magoulas L, Bruce C, et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999; 19:1105-1110.
5. Foger B, Chase M, Amar MJ, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999; 274:36912-36920.
6. Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqlB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000; 20:1323-1329.
7. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, et al. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation 2000; 102:2197-2203.
8. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000; 101:1907-1912.
9. Inazu A, Koizumi J, Mabuchi H. Cholesteryl ester transfer protein and atherosclerosis. Curr Opin Lipidol 2000; 11:389-396.
10. Yamashita S, Hirano K, Sakai N, et al. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta 2000; 1529:257-275.
11. Barter PJ, Rye KA, Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol 2001; 12:377-382.
12. Jap TS, Wu YC, Tso YC, et al. A novel mutation in the intron 1 splice donor site of the cholesterol ester transfer protein (CETP) gene as a cause of hyperalphalipoproteinemia. Metabolism 2002; 51:394-397. The authors provide a description of a novel splice site mutation in intron 1 leading to a frameshift mutation in a subject with severe hyperalphalipoproteinemia.
13. Nagano M, Yamashita S, Hirano K, et al. Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay. J Lipid Res 2002; 43:1011-1018. This describes the identification of two novel missense mutations in exons 5 and 9 of the CETP gene in compound heterozygous patients with D442G mutation. The two CETP mutants showed a markedly reduced secretion into media when expressed in COS-7 cells.
14. Parra HJ, Arveiler D, Evans AE, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992; 12:701-707.
15. Le Goff W, Guerin M, Nicaud V, et al. A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma high-density lipoprotein cholesterol levels. Interaction with the TaqlB and -629C/A polymorphisms. Atherosclerosis 2002; 161:269-279. This is a description of a novel promoter polymorphism at position -971 and its associations with other CETP variants. -971G/A did not alter transcriptional activity of the CETP promoter in transfection experiments.
16. Hsu LA, Ko YL, Hsu KH, et al. Genetic variations in the cholesteryl ester transfer protein gene and high density lipoprotein cholesterol levels in Taiwanese Chinese. Hum Genet 2002; 110:57-63. CETP variants TaqlB and D442G seem to explain a significant proportion of the variability in HDL cholesterol in Taiwanese Chinese patients. These associations were not observed in obese patients and found diminished in hypertriglyceridemic patients.
17. Eiriksdottir G, Bolla MK, Thorsson B, et al. The -629C > A polymorphism in the CETP gene does not explain the association of TaqlB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis 2001; 159:167-192. This study described an association between TaqlB polymorphism and risk for myocardial infarction. Additionally, a strong association of the - 629 A allele with the TaqlB B2 allele was observed, but the polymorphism -629C/A could not explain the association between TaqlB polymorphism and myocardial infarction risk.
18. Carr MC, Ayyobi AF, Murdoch SJ, et al. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol 2002; 22:667-673. Besides data concerning various lipoprotein modifying enzymes in 120 normolipidemic premenopausal women this study showed that TaqlB polymorphism appears to be associated with HDL3 cholesterol and CETP mass, but not with LDL buoyancy.
19. Zhuang Y, Wang J, Qiang H, et al. Cholesteryl ester transfer protein levels and gene deficiency in Chinese patients with cardio-cerebrovascular diseases. Chin Med J (Engl) 2002; 115:371-374.
20. Okumura K, Matsui H, Kamiya H, et al. Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size. Atherosclerosis 2002; 161:425-431. In this study genotype VV of polymorphism 1405V was identified as a determinant of LDL size, whereas no association was found between LDL size and TaqlB. This apparent discrepancy may explain the differential effects of these polymorphisms on the risk for CAD.
21. Kawasaki I, Tahara H, Emoto M, et al. Relationship between TaqlB cholesteryl ester transfer protein gene polymorphism and macrovascular complications in Japanese patients with type 2 diabetes. Diabetes 2002; 51:871-874. The association between TaqlB and risk for CAD was confirmed in type II diabetic patients where subjects carrying the B1B1 genotype showed higher prevalence of macrovascular complications including CAD, peripheral vascular risk and cerebrovascular disease.
22. Goto A, Sasai K, Suzuki S, et al. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. Atherosclerosis 2001; 159:153-163. In Japanese patients referred for coronary angiography 1405V and TaqlB were not associated with CAD risk. However, an association between CETP mass and TaqlB was found in patients with low coronary score suggesting that the B2 allele is only effective when it lowers CETP.
23. Arashiro R, Katsuren K, Maung KK, et al. Effect of a common mutation (D442G) of the cholesteryl ester transfer protein gene on lipids and lipoproteins in children. Pediatr Res 2001; 50:455-459. The reported association between CETP mutation D442G and HDL cholesterol was not observed in children suggesting that in children less CETP is required for efficient cholesteryl ester clearance than in older subjects.
24. Talmud PJ, Hawe E, Robertson K, et al. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet 2002; 66:111-124. Influence of genetic and environmental factors on plasma HDL cholesterol and apolipoprotein AI levels were determined in more than 3000 patients. Influence of smoking on the association between TaqlB allele and HDL cholesterol was only seen in the lowest triglyceride tertile. The authors added a profound and interesting discussion of the data presented in comparison with data from previous studies.
25. Brousseau ME, O'Connor Jr JJ, Ordovas JM, et al. Cholesteryl ester transfer protein Taql B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002; 22:1148-1154. This interesting study demonstrated a reduced frequency of the TaqlB B2 allele in patients with established coronary heart disease and HDL deficiency suggesting that increased HDL cholesterol levels resulting from decreased CETP activity are associated with lower coronary heart disease risk. Patients with two B2 alleles had the least favorable plasma lipid profile but showed the greatest lipid lowering response to gemfibrozil.
26. Wilund KR, Ferrell RE, Phares DA, et al. Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype. Metabolism 2002; 51:774-778.
27. Chen J, Yokoyama T, Saito K, et al. Association of human cholesteryl ester transfer protein-Taql polymorphisms with serum HDL cholesterol levels in a normolipemic Japanese rural population. J Epidemiol 2002; 12:77-84.
28. Heilbronn LK, Noakes M, Clifton PM. Association between HDL-cholesterol and the Taq1B polymorphism in the cholesterol ester transfer protein gene in obese women. Atherosclerosis 2002; 162:419-424. In obese women the well known association between TaqlB polymorphism and HDL cholesterol was only seen in patients with low insulin levels suggesting that insulin resistance but not obesity attenuates this association.
29. Plat J, Mensink RP. Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption. Eur J Clin Invest 2002; 32:242-250.
30. Arca M, Montali A, Ombres D, et al. Lack of association of the common TaqlB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. Clin Genet 2001; 60:374-380. In an Italian population the often found association between TaqlB polymorphism and HDL cholesterol was only seen in control subjects but not in patients referred for coronary angiography. Additionally, the TaqlB2 allele was not found to be associated with angiographically assessed coronary atherosclerosis.
31. Liu S, Schmitz C, Stampfer MJ, et al. A prospective study of TaqlB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 2002; 161:469-474. In a cohort of apparently healthy middle-aged men the risk of developing myocardial infarction did not differ between carriers of TaqlB B1 and B2 genotype.
32. Hamdy SI, Hiratsuka M, Narahara K, et al. Allele and genotype frequencies of polymorphic DCP1, CETP, ADRB2, and HTR2A in the Egyptian population. Eur J Clin Pharmacol 2002; 58:29-36.
33. Cuchel M, Wolfe ML, deLemos AS, et al. The frequency of the cholesteryl ester transfer protein-Taql B2 allele is lower in African Americans than in Caucasians. Atherosclerosis 2002; 163:169-174. The well known association between TaqlB B2 genotype and increased HDL cholesterol is unlikely to contribute to the elevated levels of HDL cholesterol in African Americans as this genotype is less frequent in this population than in any other ethnic group studied so far.
34. Knoblauch H, Bauerfeind A, Krahenbuhl C, et al. Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population. Hum Mol Genet 2002; 11:1477-1485. This is the first and only single nucleotide polymorphism haplotype study to date concerning six relevant lipid metabolism genes and their association with lipid levels. A clear association was found between CETP haplotypes and HDL cholesterol and HDL/LDL ratio promising a new tool for identifying the genetic background for atherosclerosis.
35. Nagasaka H, Chiba H, Kikuta H, et al. Unique character and metabolism of high density lipoprotein (HDL) in fetus. Atherosclerosis 2002; 161:215-223. By analysis of polymorphism D442G and concentration of CETP in cord blood this study suggests that HDL metabolism in the fetus is distinct from that in adult blood with CETP not being a limiting factor for HDL clearance.
36. Collet X, Tall AR, Serajuddin H, et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 1999; 40:1185-1193.
37. Mann CJ, Yen FT, Grant AM, et al. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991; 88:2059-2066.
38. Foger B, Ritsch A, Doblinger A, et al. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol: studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996; 16:1430-1436.
39. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338:86-93.
40. Wang J, Qiang H, Chen D, et al. CETP gene mutation (D442G) increases low-density lipoprotein particle size in patients with coronary heart disease. Clin Chim Acta 2002; 322:85-90. The major peak size of LDL in CHD patients carrying the D442G mutation was larger than in patients without the mutation suggesting an anti-atherogenic role of CETP.
41. Edwards KL, Talmud PJ, Newman B, et al. Lipoprotein candidate genes for multivariate factors of the insulin resistance syndrome: a sib-pair linkage analysis in women twins. Twin Res 2001; 4:41-47.
42. Wu JH, Lee YT, Hsu HC, et al. Influence of CETP gene variation on plasma lipid levels and coronary heart disease: a survey in Taiwan. Atherosclerosis 2001; 159:451-458.
43. Carmena-Ramon R, Ascaso JF, Real JT, et al. Association between the TaqlB polymorphism in the cholesteryl ester transfer protein gene locus and plasma lipoprotein levels in familial hypercholesterolemia. Metabolism 2001; 50:651-656.
44. Hoppe C, Cheng S, Grow M, et al. A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. Br J Haematol 2001; 114:718-720.
45. Pallaud C, Sass C, Zannad F, et al. APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort). Clin Genet 2001; 59:316-324.
46. Epps DE, Vosters AF. The essential role of a free sulfhydryl group in blocking the cholesteryl site of cholesteryl ester transfer protein (CETP). Chem Phys Lipids 2002; 114:113-122. This study provides evidence for the presence of an unpaired cysteine residue at the active site of cynomolgous monkey CETP. Conclusively, CETP inhibitors targeting this residue may act by producing steric hindrances for cholesteryl ester transfer activity.
47. Durley RC, Grapperhaus ML, Hickory BS, et al. Chirat N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein. J Med Chem 2002; 45:3891-3904. Description of the development of a novel acyclic CETP inhibitor with submicromolar potency in plasma, which led to decreased cholesteryt ester transfer and increased HDL cholesterol in CETP transgenic mice. Interestingly, R-chirality was shown to be the key for the high potency of this compound.
48. Cho KH, Lee JY, Choi MS, et al. Interaction of CETP inhibitory peptide and lipoprotein substrates in cholesteryl ester transfer assay: relationship between association properties and inhibitory activities. Lipids 2002; 37:641-646.
49. Gautier T, Masson D, Jong MC, et al. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice. J Biol Chem 2002; 277:31354-31363. This is a convincing paper providing evidence for a direct role of apolipoprotein CI in lipoprotein metabolism in mice. In several in-vivo experiments employing CETP transgenic/apolipoprotein CI knockout mice and in additional in-vitro studies apolipoprotein CI could be shown to inhibit CETP-catalyzed lipid exchange processes.
50. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atheroscierosis in rabbits. Nature 2000; 406:203-207.
51. Kobayashi J, Okamoto H, Otabe M, et al. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis 2002; 162:131-135.
52. Morton RE, Zilversmit DB. A plasma inhibitor of triglyceride and cholesteryl ester transfer activities. J Biol Chem 1981; 256:11992-11995.
53. Wang X, Driscoll DM, Morton RE. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 1999; 274:1814-1820.
54. Morton RE, Greene DJ. Regulation of lipid transfer between lipoproteins by an endogenous plasma protein: selective inhibition among lipoprotein classes. J Lipid Res 1994; 35:836-847.
55. Morton RE, Nunes V, Izem L, et al. Markedly elevated lipid transfer inhibitor protein in hypercholesterolemic subjects is mitigated by plasma triglyceride levers. Arterioscler Thromb Vasc Biol 2001; 21:1642-1649. This interesting study not only described a three-fold increased plasma concentration of lipid transfer inhibitor protein in hypercholesterolemic patients, but also a negative correlation between levels of LTIP and triglyceride in plasma possibly resulting from redistribution of LTIP from LDL to very low-density lipoprotein and subsequent increased clearance from the circulation.
56. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105:2159-2165. This was the first clinical study to employ a CETP inhibitory compound. Treatment of healthy subjects with CETP inhibitor JTT-705 led to the desired changes in lipoprotein profile including increase of HDL cholesterol and decrease of LDL cholesterol after 4 weeks.